Ruchir Sehra

Ruchir Sehra

Ruchir Sehra, M.D., is a medtech executive with extensive experience in early (private), mid (public), and late stage (acquisition) medical device companies in various health and disease areas. Dr. Sehra currently serves as the CEO and President of Resonea, Inc, which was founded in 2016. Resonea’s mission is to develop a new standard for understanding sleep breathing and its impact on the human condition. Dr. Sehra was previously the Chief Medical Officer of Abbott Electrophysiology, joining Abbott through the acquisition of Topera, Inc., a company which he co-founded and served as it’s CMO. Topera was a venture-backed medical device company that developed a novel 3-D analysis and mapping system to assist electrophysiologists in the identification of the electrical source of complex cardiac arrhythmias.

Prior to Topera, Dr. Sehra worked to help evaluate numerous medtech and biotech companies for venture capital and private equity investors. He had previously served the Chief Medical Officer or VP of Clinical/Medical Affairs/Professional Education of a number of other medical device companies in the areas of stroke, spinal disease, heart rhythm disorders, interventional cardiology and interventional neuroradiology. One of these companies, Kyphon was the largest medical device start-up acquisition ($4.2 Billion) in the past decade, becoming part of Medtronic’s Spinal and Biologics Business in November 2007.

Before working in the medical technology industry, Dr. Sehra was Associate Professor of Pediatrics and Medicine at Loma Linda University where he practiced full-time electrophysiology and was Director of Business Operations for an 85-physician practice.

Dr. Sehra received his B.A. from Wabash College and his M.D. from Indiana University School of Medicine. He also received an MBA from the University of California, Irvine. He is currently an Adjunct Professor with the School of Biological and Health Systems Engineering at Arizona State University.

He is also a named inventor on nearly 100 worldwide patents.